{"altmetric_id": 90029906, "counts": {"readers": {"citeulike": "0", "mendeley": "94", "connotea": "0"}, "total": {"posts_count": 109}, "twitter": {"unique_users_count": 60, "posts_count": 65}, "news": {"unique_users_count": 20, "unique_users": ["the_medical_news", "chemical_engineering_news", "trialsite_news", "marketscreener", "tcmnet_com", "stockwatch", "globenewswire", "jotup", "biz_wire_express", "crwe_world", "yahoo_finance_usa", "benzinga", "the_street", "morning_star", "spoke", "biospace", "vb_profiles", "futures_tradingcharts_com", "biomed_reports", "spektrum"], "posts_count": 43}, "blogs": {"unique_users_count": 1, "unique_users": [52246], "posts_count": 1}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["Boras, Britton", "Jones, Rhys M.", "Anson, Brandon J.", "Arenson, Dan", "Aschenbrenner, Lisa", "Bakowski, Malina A.", "Beutler, Nathan", "Binder, Joseph", "Chen, Emily", "Eng, Heather", "Hammond, Holly", "Hammond, Jennifer", "Haupt, Robert E.", "Hoffman, Robert", "Kadar, Eugene P.", "Kania, Rob", "Kimoto, Emi", "Kirkpatrick, Melanie G.", "Lanyon, Lorraine", "Lendy, Emma K.", "Lillis, Jonathan R.", "Logue, James", "Luthra, Suman A.", "Ma, Chunlong", "Mason, Stephen W.", "McGrath, Marisa E.", "Noell, Stephen", "Obach, R. Scott", "O\u2019Brien, Matthew N.", "O\u2019Connor, Rebecca", "Ogilvie, Kevin", "Owen, Dafydd", "Pettersson, Martin", "Reese, Matthew R", "Rogers, Thomas F.", "Rossulek, Michelle I.", "Sathish, Jean G.", "Shirai, Norimitsu", "Steppan, Claire", "Ticehurst, Martyn", "Updyke, Lawrence W.", "Weston, Stuart", "Zhu, Yuao", "Wang, Jun", "Chatterjee, Arnab K.", "Mesecar, Andrew D.", "Frieman, Matthew B.", "Anderson, Annaliesa S.", "Allerton, Charlotte"], "doi": "10.1101/2020.09.12.293498", "first_seen_on": "2020-09-13T22:00:57+00:00", "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1620071272, "links": ["https://www.biorxiv.org/content/10.1101/2020.09.12.293498v1", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v1.full.pdf", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2.article-info", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2", "http://dx.doi.org/10.1101/2020.09.12.293498", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v1.full", "https://doi.org/10.1101/2020.09.12.293498", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v3", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v3.full.pdf", "https://www.biorxiv.org/content/10.1101/2020.09.12.293498v3.full"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/09/13/2020.09.12.293498.full.pdf", "pmid": "32935104", "publisher": "Cold Spring Harbor Laboratory", "title": "Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/7b3771e0-8c78-3851-98a1-9ca441ef413e/"}, "altmetric_score": {"score": 177.78, "score_history": {"1y": 177.78, "6m": 131.08, "3m": 124.5, "1m": 11.75, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 177.78}, "context_for_score": {"all": {"total_number_of_other_articles": 17690819, "mean": 9.4363188551043, "rank": 124667, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 17566350, "rank_type": "exact", "sample_size": 17690819, "percentile": 99}, "similar_age_3m": {"total_number_of_other_articles": 309330, "mean": 18.099939449778, "rank": 4832, "this_scored_higher_than_pct": 98, "this_scored_higher_than": 304502, "rank_type": "exact", "sample_size": 309330, "percentile": 98}, "this_journal": {"total_number_of_other_articles": 120714, "mean": 13.885483125404, "rank": 703, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 120037, "rank_type": "exact", "sample_size": 120714, "percentile": 99}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 9030, "mean": 13.098651605759, "rank": 52, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 8978, "rank_type": "exact", "sample_size": 9030, "percentile": 99}}}, "demographics": {"poster_types": {"member_of_the_public": 41, "researcher": 17, "practitioner": 2}, "users": {"twitter": {"cohorts": {"Members of the public": 41, "Scientists": 17, "Practitioners (doctors, other healthcare professionals)": 2}}, "mendeley": {"by_status": {"Student  > Postgraduate": 2, "Professor > Associate Professor": 1, "Researcher": 19, "Student  > Master": 12, "Student  > Ph. D. Student": 15, "Professor": 5, "Student  > Bachelor": 9, "Student  > Doctoral Student": 2, "Other": 4, "Librarian": 2, "Unspecified": 3}, "by_discipline": {"Medicine and Dentistry": 7, "Social Sciences": 1, "Psychology": 1, "Mathematics": 1, "Pharmacology, Toxicology and Pharmaceutical Science": 9, "Environmental Science": 2, "Unspecified": 3, "Arts and Humanities": 1, "Chemistry": 23, "Economics, Econometrics and Finance": 1, "Immunology and Microbiology": 3, "Earth and Planetary Sciences": 1, "Agricultural and Biological Sciences": 6, "Nursing and Health Professions": 2, "Biochemistry, Genetics and Molecular Biology": 12}}}, "geo": {"twitter": {"US": 11, "FR": 5, "FI": 1, "AU": 1, "ES": 2, "DE": 2, "GB": 2, "TR": 1, "IT": 1, "PK": 1, "BE": 1, "PA": 2, "CA": 1, "PR": 1, "EG": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1305265167106744320"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "4739609663"}, "tweet_id": "1305281541254324225"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "373113388"}, "tweet_id": "1305287980198899715"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "111029613"}, "tweet_id": "1305297960889184259"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "392413519"}, "tweet_id": "1305357665992933376"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1120536353853386753"}, "tweet_id": "1305360498666491905"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "79570177"}, "tweet_id": "1305361740365025280"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "319669492"}, "tweet_id": "1305362452784189442"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "510816105"}, "tweet_id": "1305373807788650496"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "11976432"}, "tweet_id": "1305375246107594752"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "3142088601"}, "tweet_id": "1305400855777234945"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "93142657"}, "tweet_id": "1305422702430257152"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1136370591517290496"}, "tweet_id": "1305429057195126785"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "895590566280417281"}, "tweet_id": "1305445785413197824"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1192200938074890241"}, "tweet_id": "1305463232585441285"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "170479033"}, "tweet_id": "1305474599229022208"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "3133960869"}, "tweet_id": "1305480878777401345"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "334270772"}, "tweet_id": "1305497713425952771"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1247376635004936192"}, "tweet_id": "1305512045429825544"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "930505711"}, "tweet_id": "1305525893087936512"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1240556073259601920"}, "tweet_id": "1305525908879466497"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "392413519"}, "tweet_id": "1305564902455734272"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "2631088551"}, "tweet_id": "1305565634860847104"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "139358002"}, "tweet_id": "1305570757062406150"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "907273215893962752"}, "tweet_id": "1305571360043864073"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "26924020"}, "tweet_id": "1305578596371554304"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "392413519"}, "tweet_id": "1305586796617781251"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1255879500031840261"}, "tweet_id": "1305599465072586758"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1649910906"}, "tweet_id": "1305620491751665664"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1305841652792266752"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1305841674740998144"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1305843209390653445"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "2166933879"}, "tweet_id": "1305908742790279168"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "92307465"}, "tweet_id": "1305934421992837121"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "995002926446850049"}, "tweet_id": "1305970786608599048"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1242751811620081664"}, "tweet_id": "1305971391561375752"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1306027430214213632"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1283825867731263488"}, "tweet_id": "1306103504683954176"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "758224136611168256"}, "tweet_id": "1306118224145195008"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "856022521577168896"}, "tweet_id": "1306149440403767296"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "892120710667264001"}, "tweet_id": "1306195686820544512"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "363320406"}, "tweet_id": "1306704685772963841"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "2651437977"}, "tweet_id": "1306855880995078144"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1230288342073380864"}, "tweet_id": "1308402820538945537"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "3372994217"}, "tweet_id": "1308437658742525952"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "863893550"}, "tweet_id": "1308439653222096896"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "43342972"}, "tweet_id": "1308588064965623810"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "202836527"}, "tweet_id": "1311846307657519104"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "19240173"}, "tweet_id": "1315867997555302405"}, {"license": "gnip", "citation_ids": [89098561, 90029906], "author": {"tweeter_id": "1237188964546760705"}, "tweet_id": "1322992188435955714"}, {"license": "gnip", "citation_ids": [89098561, 90029906], "author": {"tweeter_id": "1237188964546760705"}, "tweet_id": "1323019360026480642"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "582413884"}, "tweet_id": "1332122079227904000"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "141393630"}, "tweet_id": "1360569521392807937"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1046555028461408261"}, "tweet_id": "1360859742122500098"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1085228274899447808"}, "tweet_id": "1365955877447094273"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "427679963"}, "tweet_id": "1366213101721448449"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "817934777915314178"}, "tweet_id": "1371835950184140809"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "1277613275530788866"}, "tweet_id": "1374431747425771526"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "804283376228306944"}, "tweet_id": "1374690699103322118"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "17684875"}, "tweet_id": "1374905941863325698"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "583052859"}, "tweet_id": "1375950953820618763"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "216312099"}, "tweet_id": "1380112317174714368"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "738439058"}, "tweet_id": "1387735130370940930"}, {"license": "gnip", "citation_ids": [90029906, 100033922], "author": {"tweeter_id": "1352919297878843393"}, "tweet_id": "1388354830750687233"}, {"license": "gnip", "citation_ids": [90029906], "author": {"tweeter_id": "119049059"}, "tweet_id": "1389305728737890304"}], "news": [{"title": "Pfizer's anti-viral 3CL protease inhibitor shows antiviral potential against SARS-CoV-2", "url": "http://ct.moreover.com/?a=43086778282&p=1pl&v=1&x=HPyIqOZhkSKwESjS1xy02w", "license": "public", "citation_ids": [90029906], "posted_on": "2020-09-16T07:11:53+00:00", "summary": "The COVID-19 pandemic has still not been countered by effective drugs or antivirals, which is the reason for the continued restrictions on mobility and social interactions in most countries the world over.", "author": {"name": "The Medical News", "url": "http://www.news-medical.net/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/146/normal/image.png?1369927508"}}, {"title": "Pfizer\u2019s novel COVID-19 antiviral heads to clinical trials", "url": "http://ct.moreover.com/?a=43100029087&p=1pl&v=1&x=jmn3hsZPnM70YXsCUIT8gQ", "license": "public", "citation_ids": [90029906], "posted_on": "2020-09-17T18:25:51+00:00", "summary": "Drugmaker Pfizer has begun Phase 1 clinical tests of PF-07304814, a small molecule that could be used to fight SARS-CoV-2, the virus that causes COVID-19.", "author": {"name": "Chemical & Engineering News", "url": "http://cen.acs.org/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/095/normal/C_ENNameplate.jpg?1561999883"}}, {"title": "Pfizer Takes Antiviral Drug PF-07304814 into Phase 1 Clinical Trial Targeting COVID-19", "url": "https://www.trialsitenews.com/pfizer-takes-antiviral-drug-pf-07304814-into-phase-1-clinical-trial-targeting-covid-19/", "license": "public", "citation_ids": [89098561, 90029906, 89281512], "posted_on": "2020-09-21T21:30:07+00:00", "summary": "Pfizer has initiated a Phase 1 clinical trial for a novel small molecule called PF-07304814, a compound targeting an enzyme that SARS-COV-2 uses to organize and multiply\u2014the 3CL protease.", "author": {"name": "TrialSite News", "url": "https://www.trialsitenews.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/110/normal/Screenshot_2019-07-12_at_12.25.34.png?1562930787"}}, {"title": "Pfizer\u2019s novel COVID-19 antiviral heads to clinical trials", "url": "http://ct.moreover.com/?a=43170615427&p=1pl&v=1&x=C8JelGDVsfPZJ4R8oNXmyQ", "license": "public", "citation_ids": [90029906], "posted_on": "2020-09-26T10:08:45+00:00", "summary": "Drugmaker Pfizer has begun Phase 1 clinical tests of PF-07304814, a small molecule that could be used to fight SARS-CoV-2, the virus that causes COVID-19.", "author": {"name": "Chemical & Engineering News", "url": "http://cen.acs.org/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/095/normal/C_ENNameplate.jpg?1561999883"}}, {"title": "TODOS MEDICAL : Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen", "url": "http://ct.moreover.com/?a=43429674380&p=1pl&v=1&x=NzpavoQzZTyp7r2L_xcK-w", "license": "public", "citation_ids": [90029906], "posted_on": "2020-10-29T12:00:05+00:00", "summary": "Tollovid is a proprietary blend of plant extracts administered orally as dietary supplement The granted a Certificate of Free Sale for Tollovid on August 28, 2020 Tollovid ingredients inhibit the 3CL protease, a key protease required for\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen", "url": "http://ct.moreover.com/?a=43429686412&p=1pl&v=1&x=5hWVLIv5CFIvkogOdWo2Fw", "license": "public", "citation_ids": [90029906], "posted_on": "2020-10-29T12:04:00+00:00", "summary": "] Tollovid is a proprietary blend of plant extracts administered orally as dietary supplement The US FDA granted a Certificate of Free Sale for Tollovid on August 28, 2020 Tollovid ingredients inhibit the 3CL protease, a key protease required for\u2026", "author": {"name": "TMCnet.com", "url": "http://www.tmcnet.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/169/normal/Screen_Shot_2014-10-01_at_14.45.46.png?1412171168"}}, {"title": "Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen", "url": "http://ct.moreover.com/?a=43429688478&p=1pl&v=1&x=w5n3avzqpwAjrnQ4TN68kA", "license": "public", "citation_ids": [90029906], "posted_on": "2020-10-29T12:04:19+00:00", "summary": "Tollovid is a proprietary blend of plant extracts administered orally as dietary supplement The US FDA granted a Certificate of Free Sale for Tollovid on August 28, 2020 Tollovid ingredients inhibit the 3CL protease, a key protease required for\u2026", "author": {"name": "Stockwatch", "url": "https://www.stockwatch.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/797/normal/Capture19.PNG?1576480973"}}, {"title": "Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen", "url": "http://ct.moreover.com/?a=43429692494&p=1pl&v=1&x=R_-BMA2vwuir-TE-1AZWGA", "license": "public", "citation_ids": [90029906], "posted_on": "2020-10-29T12:00:00+00:00", "summary": "Tollovid is a proprietary blend of plant extracts administered orally as dietary supplement The US FDA granted a Certificate of Free Sale for Tollovid on August 28, 2020 Tollovid ingredients inhibit the 3CL protease, a key protease required for\u2026", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen", "url": "http://ct.moreover.com/?a=43429815667&p=1pl&v=1&x=G8lfm0lzz7FCBjFfVL4uFg", "license": "public", "citation_ids": [90029906], "posted_on": "2020-10-29T12:21:27+00:00", "summary": "Todos licensed the exclusive worldwide distribution rights for Tollovid, excluding Israel, from Israel-based joint venture partner NLC Pharma in September 2020.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen", "url": "http://ct.moreover.com/?a=43430346197&p=1pl&v=1&x=OhTSxM97II-nx9RryWL3ow", "license": "public", "citation_ids": [90029906], "posted_on": "2020-10-29T13:26:55+00:00", "summary": "NewMediaWire 2020-10-29 \u00b7 Tollovid is a proprietary blend of plant extracts administered orally as dietary supplement \u00b7 The US FDA granted a Certificate of Free Sale for Tollovid on August 28, 2020 \u00b7 Tollovid ingredients inhibit the 3CL protease, a\u2026", "author": {"name": "Biz Wire Express", "url": "http://www.bizwireexpress.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/795/normal/Screen_Shot_2016-01-27_at_09.34.21.png?1453887297"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434254441&p=1pl&v=1&x=50ayl5nXxsvgV5UNL1MIlQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:01:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434284948&p=1pl&v=1&x=eK6hvJk6gPj8ztIYENgpeQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:05:53+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "Stockwatch", "url": "https://www.stockwatch.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/797/normal/Capture19.PNG?1576480973"}}, {"title": "TODOS MEDICAL : Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434289387&p=1pl&v=1&x=i-4uR_AO4uQwUb7OAbeQpQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:02:33+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434296756&p=1pl&v=1&x=PEiSY4XaDrF0tNTKtUM3qg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:07:48+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "TMCnet.com", "url": "http://www.tmcnet.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/169/normal/Screen_Shot_2014-10-01_at_14.45.46.png?1412171168"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434300023&p=1pl&v=1&x=6Z7g1rBVNyaP87NyFYKGsg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:08:24+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434334463&p=1pl&v=1&x=ujVgjEvsg2CiaR2_X5Hdbw", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:01:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "Yahoo! Finance USA", "url": "http://finance.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/620/normal/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434358601&p=1pl&v=1&x=Gjpj2tvBt2ed268MkpGLRw", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:01:29+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "Todos Medical Applauds Senate And House Passage Of The American Recovery Act", "url": "http://ct.moreover.com/?a=44434372308&p=1pl&v=1&x=Z8g3QgJA6KnyKhKG3lpuyQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:01:29+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434424629&p=1pl&v=1&x=XlJiiWHj_dbZcGnMrv8rhg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:28:50+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- \u00c2 via NewMediaWire\u00c2 --\u00c2 Todos Medical, Ltd.", "author": {"name": "Biz Wire Express", "url": "http://www.bizwireexpress.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/795/normal/Screen_Shot_2016-01-27_at_09.34.21.png?1453887297"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434560738&p=1pl&v=1&x=zpjchXwCFPDBNOqbEHRhxg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:01:29+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434610265&p=1pl&v=1&x=UZmvYbjm3HP2dyZ_HR3sew", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T15:58:02+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --, an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood\u2026", "author": {"name": "Spoke", "url": "http://www.spoke.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/787/normal/Capture14.PNG?1576476237"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44434972073&p=1pl&v=1&x=dkIh67jmjf7moqPRTWptxA", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T16:51:07+00:00", "summary": "The US Federal Government is responding appropriately given the scale of the COVID-19 problem we face, said Gerald Commissiong, President & CEO of Todos Medical.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "Todos Medical Applauds Senate and House Passage of the American Recovery Act", "url": "http://ct.moreover.com/?a=44440365251&p=1pl&v=1&x=93m9Oz4ZixgAZTj7PRpX-g", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-11T00:00:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 11, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442850169&p=1pl&v=1&x=sa3XQEPLF7V2BZRF3F0rDw", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:40:37+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "Stockwatch", "url": "https://www.stockwatch.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/797/normal/Capture19.PNG?1576480973"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442864734&p=1pl&v=1&x=jHugpGFhuA6K7zX7wfpdcw", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:40:02+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442856815&p=1pl&v=1&x=0d2QuyS4PJKWRq3GFByVbg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T00:00:00+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442866466&p=1pl&v=1&x=BAfxnNWJ0FiDG5PDx41pXQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:42:09+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "TMCnet.com", "url": "http://www.tmcnet.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/169/normal/Screen_Shot_2014-10-01_at_14.45.46.png?1412171168"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442903327&p=1pl&v=1&x=D0g4mWYcKToOR4llwGKpTA", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:48:28+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442930166&p=1pl&v=1&x=G4U35SeHIP5S6TXiaGQjhg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:39:00+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "Yahoo! Finance USA", "url": "http://finance.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/620/normal/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442936546&p=1pl&v=1&x=6n0RU2p6Zi8-WeaN69X9jg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:39:51+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44442969452&p=1pl&v=1&x=lJ7ENpa339VcMZCmmW-dLw", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:58:35+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "VB Profiles", "url": "https://www.vbprofiles.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/839/normal/58.JPG?1576557158"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44443252677&p=1pl&v=1&x=LqUTBRrfxnNr8M9xw2PqhQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T14:39:51+00:00", "summary": "\u00b7 $12.5M in combined January 2021 and February 2021 sales \u00b7 President Biden signs American Recovery Act into law NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44443926673&p=1pl&v=1&x=3z2G583OTxLbetrV1g0tmA", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T17:18:13+00:00", "summary": "Additionally, Todos expects another one of its pending NYC Tri-State Area clients to become operational and begin to bring sample processing in-house in the coming weeks.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021", "url": "http://ct.moreover.com/?a=44444216423&p=1pl&v=1&x=9xbKAuexaAPHvR0Edz5F_g", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-12T18:05:51+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, March 12, 2021 (GLOBE NEWSWIRE) -- -- Todos Medical, Ltd.", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44524193118&p=1pl&v=1&x=FZhCrQyZ6JOzbO43GuGzsw", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-23T12:00:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via \u2013 Todos Medical, Ltd.", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "TODOS MEDICAL : Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44524219888&p=1pl&v=1&x=L4WI3g_QNvZbrtVC5BZkqg", "license": "public", "citation_ids": [90029906, 87092610], "posted_on": "2021-03-23T12:01:44+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \u2013 (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44524239765&p=1pl&v=1&x=9hVAOin-fMLOrYvGYFMzjQ", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-23T12:00:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \u2013 Todos Medical, Ltd.", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44524247189&p=1pl&v=1&x=lWaxIaYyDXf6URtR6sudNg", "license": "public", "citation_ids": [90029906, 87092610, 87092610], "posted_on": "2021-03-23T12:09:41+00:00", "summary": "via NewMediaWire - Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for early detection of\u2026", "author": {"name": "Futures TradingCharts.com", "url": "https://futures.tradingcharts.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/383/normal/Capture_future.PNG?1574943251"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44524295624&p=1pl&v=1&x=8lXZrxS4WNTszwJ6FraC-g", "license": "public", "citation_ids": [90029906, 87092610], "posted_on": "2021-03-23T12:00:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \u2013 Todos Medical, Ltd.", "author": {"name": "Yahoo! Finance USA", "url": "http://finance.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/620/normal/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44524322789&p=1pl&v=1&x=bDTush37xEyP3kDo82Mu5Q", "license": "public", "citation_ids": [90029906, 87092610], "posted_on": "2021-03-23T07:00:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 ( ) NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \u2013 Todos Medical, Ltd.", "author": {"name": "BioMed Reports", "url": "http://www.biomedreports.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/913/normal/Screen_Shot_2016-02-02_at_15.18.15.png?1454426307"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44525069605&p=1pl&v=1&x=Dy08tgcHR3i6yC5JZ9oM7A", "license": "public", "citation_ids": [90029906, 87092610], "posted_on": "2021-03-23T14:08:30+00:00", "summary": "Upon completion of the automation process, MAJL will be capable of processing approximately 1,500 PCR COVID-19 tests per day.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics", "url": "http://ct.moreover.com/?a=44525083323&p=1pl&v=1&x=E7bo2_DQjyPha6PX88ADgA", "license": "public", "citation_ids": [90029906, 87092610], "posted_on": "2021-03-23T00:00:00+00:00", "summary": "NEW YORK, NY, REHOVAT, ISRAEL, and ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via \u2013 Todos Medical, Ltd.", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "Antivirale Medikamente: Der Wirkstoff gegen das n\u00e4chste Pandemievirus", "url": "http://ct.moreover.com/?a=44794852206&p=1pl&v=1&x=CY91M9u2f6Nc-dAfc1_WSg", "license": "public", "citation_ids": [3051575, 21398924, 82566104, 95341045, 79209935, 94482722, 50436981, 92460355, 90029906], "posted_on": "2021-04-28T06:38:05+00:00", "summary": "Antivirale Medikamente: Der Wirkstoff gegen das n\u00e4chste Pandemievirus Warnungen gab es viele, beherzigt wurden sie nicht: Corona traf die Medikamentenentwickler unvorbereitet.", "author": {"name": "Spektrum", "url": "http://www.spektrum.de/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/917/normal/Screen_Shot_2016-02-02_at_12.11.43.png?1454415118"}}], "blogs": [{"title": "Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32", "url": "http://fbdd-lit.blogspot.com/2021/01/tom-lehrers-guide-to-design-of-sars-cov.html", "license": "public", "citation_ids": [90029906, 78690918, 26755882, 79808852, 27571258, 58613974, 97520265, 97520266, 41385788, 35255773], "posted_on": "2021-01-12T10:46:00+00:00", "summary": "&lt;&lt; previous || next &gt;&gt;It\u2019s been ages since my last COVID-19 post (How not to repurpose a 'drug') and I\u2019ll kick blogging off for 2021 with a follow up to an even older post (SARS-CoV-2 main protease. Crowdsourcing, peptidomimetics and fragments)", "author": {"name": "Fragment-Based Drug Discovery &amp; Molecular Design", "url": "http://fbdd-lit.blogspot.com/", "description": "The scope of the former FBDD Literature blog has been broadened to include Molecular Design although there'll still be plenty of fragment-based stuff. Comments are moderated so it may be a while before you see your comments appear."}}]}, "score": 177.78, "images": {"small": "https://badges.altmetric.com/?size=64&score=178&types=mmmbtttt", "medium": "https://badges.altmetric.com/?size=100&score=178&types=mmmbtttt", "large": "https://badges.altmetric.com/?size=180&score=178&types=mmmbtttt"}}